Solara Active Pharma Sciences Ltd
NSE:SOLARA

Watchlist Manager
Solara Active Pharma Sciences Ltd Logo
Solara Active Pharma Sciences Ltd
NSE:SOLARA
Watchlist
Price: 799.35 INR 4.98% Market Closed
Market Cap: 38.4B INR
Have any thoughts about
Solara Active Pharma Sciences Ltd?
Write Note

Solara Active Pharma Sciences Ltd
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Solara Active Pharma Sciences Ltd
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Solara Active Pharma Sciences Ltd
NSE:SOLARA
Accounts Receivables
â‚ą3.8B
CAGR 3-Years
-18%
CAGR 5-Years
8%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Accounts Receivables
â‚ą80.3B
CAGR 3-Years
17%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Accounts Receivables
â‚ą55.9B
CAGR 3-Years
17%
CAGR 5-Years
7%
CAGR 10-Years
13%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Accounts Receivables
â‚ą129.4B
CAGR 3-Years
9%
CAGR 5-Years
9%
CAGR 10-Years
14%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Accounts Receivables
â‚ą17.8B
CAGR 3-Years
5%
CAGR 5-Years
3%
CAGR 10-Years
4%
M
Mankind Pharma Ltd
NSE:MANKIND
Accounts Receivables
â‚ą8.5B
CAGR 3-Years
37%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Solara Active Pharma Sciences Ltd
Glance View

Market Cap
38.4B INR
Industry
Pharmaceuticals

Solara Active Pharma Sciences Ltd. engages in the manufacture and development of active pharmaceutical ingredient. The company is headquartered in Chennai, Tamil Nadu. The company went IPO on 2018-06-27. The firm is involved in contract manufacturing and development services for global companies. Its commercial products include Aprepitant (Antiemetic), Brivaracetam (Antiepileptic), Bumetanide (Inj) (Loop Diuretic), Buspirone Hcl (Anxiolytic), Cevimeline Hydrochloride (Muscarinic Agonist), Cinacalcet Hydrochloride (Calcimimetic Agent), Citicoline Sodium (Anticonvulsant), Colchicine (Antigout Agent), Disulfiram (Chronic Alcoholism), Edaravone (Recovery Of Stroke), Etomidate (Anesthetics), Felbamate (Anticonvulsant), Flecainide Acetate (Anti-Arrhythmic Agent), Rifaximin (Antibiotic), S-Ibuprofen (Anti-Inflammatory), Oseltamivir Phosphate(Antiviral) and Levetiracetam (Anticonvulsant). The company provides services, such as synthetic development, analytical development, process engineering, and regulatory services.

SOLARA Intrinsic Value
539.44 INR
Overvaluation 33%
Intrinsic Value
Price

See Also

What is Solara Active Pharma Sciences Ltd's Accounts Receivables?
Accounts Receivables
3.8B INR

Based on the financial report for Sep 30, 2024, Solara Active Pharma Sciences Ltd's Accounts Receivables amounts to 3.8B INR.

What is Solara Active Pharma Sciences Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
8%

Over the last year, the Accounts Receivables growth was -27%. The average annual Accounts Receivables growth rates for Solara Active Pharma Sciences Ltd have been -18% over the past three years , 8% over the past five years .

Back to Top